-+ 0.00%
-+ 0.00%
-+ 0.00%

LYTIX BIOPHARMA: FDA FEEDBACK CLEARS PATH TO REGISTRATIONAL PHASE III TRIAL FOR RUXOTEMITIDE (LTX-315) IN PATIENTS WITH RESECTABLE HIGH-RISK MELANOMA

Reuters·08/27/2026 04:58:40

Please log in to view news